NO961086L - Nye proteiner/polypeptider og kotransfeksjonsplasmider og levende rekombinante bærere for disse - Google Patents

Nye proteiner/polypeptider og kotransfeksjonsplasmider og levende rekombinante bærere for disse

Info

Publication number
NO961086L
NO961086L NO961086A NO961086A NO961086L NO 961086 L NO961086 L NO 961086L NO 961086 A NO961086 A NO 961086A NO 961086 A NO961086 A NO 961086A NO 961086 L NO961086 L NO 961086L
Authority
NO
Norway
Prior art keywords
proteins
protein
antigenically active
active proteins
coronavirus
Prior art date
Application number
NO961086A
Other languages
English (en)
Norwegian (no)
Other versions
NO961086D0 (no
Inventor
Michel Bublot
Catherine De Wannemaeker
Didier Colau
Philippe Roux-Salembien
Original Assignee
Solvay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay filed Critical Solvay
Publication of NO961086D0 publication Critical patent/NO961086D0/no
Publication of NO961086L publication Critical patent/NO961086L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO961086A 1993-09-16 1996-03-15 Nye proteiner/polypeptider og kotransfeksjonsplasmider og levende rekombinante bærere for disse NO961086L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9319212A GB2282601B (en) 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
PCT/EP1994/002990 WO1995007987A2 (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor

Publications (2)

Publication Number Publication Date
NO961086D0 NO961086D0 (no) 1996-03-15
NO961086L true NO961086L (no) 1996-05-09

Family

ID=10742112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961086A NO961086L (no) 1993-09-16 1996-03-15 Nye proteiner/polypeptider og kotransfeksjonsplasmider og levende rekombinante bærere for disse

Country Status (10)

Country Link
EP (1) EP0720654A1 (ko)
JP (1) JPH09509562A (ko)
KR (1) KR960705047A (ko)
AU (1) AU7615894A (ko)
BR (1) BR9407507A (ko)
CA (1) CA2171869A1 (ko)
GB (2) GB2316681B (ko)
NO (1) NO961086L (ko)
WO (1) WO1995007987A2 (ko)
ZA (1) ZA946887B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724385B1 (fr) * 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.
FR2741806B1 (fr) * 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
WO1998001570A2 (en) * 1996-07-05 1998-01-15 Vanderbilt University Mutated antibody-dependent infection enhancing domains of hiv
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
CN1223605C (zh) * 2003-05-16 2005-10-19 中国科学院微生物研究所 抑制sars冠状病毒的多肽药物及其衍生物和其应用
CN113321714B (zh) * 2020-02-28 2022-12-09 深圳市亚辉龙生物科技股份有限公司 SARS-CoV-2的重组N蛋白及其制备与纯化方法
US20230331782A1 (en) * 2020-09-08 2023-10-19 The Trustees Of The University Of Pennsylvania Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
EP0264979A1 (en) * 1986-09-05 1988-04-27 Duphar International Research B.V New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines
CA2005291C (en) * 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
CA2020740A1 (en) * 1989-07-12 1991-01-13 Harry Vennema Antigenically active proteins/peptides, and feline infectious peritonitis virus (fipv)-vaccines
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
JPH07504897A (ja) * 1992-02-18 1995-06-01 パーヘリオン　コーポレーション ネコ感染性腹膜炎ワクチンおよび調製方法
JPH07508176A (ja) * 1992-05-08 1995-09-14 ファイザー・インコーポレイテッド 普遍コロナウイルスワクチン
CA2135200C (en) * 1992-05-08 2001-03-27 Timothy J. Miller Canine coronavirus s gene and uses therefor

Also Published As

Publication number Publication date
GB2282601A (en) 1995-04-12
GB2282601B (en) 1998-04-15
EP0720654A1 (en) 1996-07-10
GB2316681B (en) 1998-04-15
GB2316681A (en) 1998-03-04
GB9319212D0 (en) 1993-11-03
NO961086D0 (no) 1996-03-15
WO1995007987A2 (en) 1995-03-23
WO1995007987A3 (en) 1995-06-22
KR960705047A (ko) 1996-10-09
AU7615894A (en) 1995-04-03
GB9722558D0 (en) 1997-12-24
JPH09509562A (ja) 1997-09-30
ZA946887B (en) 1995-06-27
BR9407507A (pt) 1997-01-07
CA2171869A1 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
NZ505322A (en) Protein expression in baculovirus vector expression systems using low multiplicity of infection
NO177678C (no) Fremgangsmåte for fremstilling av et terapeutisk aktivt, rekombinant protein som har ASP-aktivitet, ekspresjonssystem samt DNA som koder for nevnte protein
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
CA2224257A1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
NZ521270A (en) Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line
HUP0104609A2 (hu) Plazmidfenntartó rendszer antigén-bejuttatásra
MXPA01008966A (es) Vacunas contra el virus sincicial respiratorio a base de acido nucleico.
RU2001107969A (ru) Иммунодоминантный антигенный белок массой 120 кда и ген ehrlichia canis
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
NO961086L (no) Nye proteiner/polypeptider og kotransfeksjonsplasmider og levende rekombinante bærere for disse
DE68926679D1 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
ATE103297T1 (de) Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea.
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
DK457687D0 (da) Antigenisk aktive proteiner og peptider, og vacciner mod virus for felin peritonitis (fipv) med indhold af saadanne proteiner eller peptider
IL75553A0 (en) Ache like peptide
NO177859C (no) Fremgangsmåte til produksjon av angiogen faktor
WO2021207848A1 (en) Mers-cov vaccine
RU94045154A (ru) Полипептиды, их фрагменты и варианты, препарат, днк вектор, клетка, способ продукции полипептида, вакцины, способы защиты, антитело и его фрагмент, их применение, применение днк, способ идентификации антигена
RU93031157A (ru) Способ повышения продуктивности сельскохозяйственных животных с помощью химерного белка, содержащего соматостатин, иммуногенная композиция, факторы повышения продуктивности
DK204588A (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
ES2012815A6 (es) Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma, y para preparar vacunas que los contienen.